GlycoMimetics, Inc. (NASDAQ:GLYC) SVP Helen M. Thackray sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $15.01, for a total transaction of $30,020.00. Following the completion of the transaction, the senior vice president now owns 148,615 shares of the company’s stock, valued at $2,230,711.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

GlycoMimetics, Inc. (NASDAQ:GLYC) traded up $0.02 during mid-day trading on Thursday, hitting $16.47. 1,077,800 shares of the company’s stock traded hands, compared to its average volume of 945,577. GlycoMimetics, Inc. has a 52-week low of $3.82 and a 52-week high of $18.25.

GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. sell-side analysts predict that GlycoMimetics, Inc. will post -1.12 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of GLYC. Russell Investments Group Ltd. raised its stake in shares of GlycoMimetics by 172.4% during the second quarter. Russell Investments Group Ltd. now owns 31,379 shares of the biotechnology company’s stock worth $350,000 after acquiring an additional 19,859 shares in the last quarter. TD Asset Management Inc. bought a new position in shares of GlycoMimetics in the second quarter worth approximately $362,000. Bank of New York Mellon Corp grew its holdings in shares of GlycoMimetics by 159.4% in the second quarter. Bank of New York Mellon Corp now owns 92,911 shares of the biotechnology company’s stock worth $1,037,000 after purchasing an additional 57,091 shares during the last quarter. Jennison Associates LLC bought a new position in shares of GlycoMimetics in the second quarter worth approximately $17,786,000. Finally, Columbus Circle Investors bought a new position in shares of GlycoMimetics in the second quarter worth approximately $1,516,000. 86.81% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently commented on GLYC shares. BidaskClub upgraded shares of GlycoMimetics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. ValuEngine upgraded shares of GlycoMimetics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. SunTrust Banks raised their price objective on shares of GlycoMimetics to $32.00 and gave the company a “buy” rating in a research report on Tuesday. Roth Capital started coverage on shares of GlycoMimetics in a research report on Monday, October 23rd. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Friday, October 6th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. GlycoMimetics has a consensus rating of “Buy” and a consensus target price of $19.17.

COPYRIGHT VIOLATION WARNING: “Helen M. Thackray Sells 2,000 Shares of GlycoMimetics, Inc. (GLYC) Stock” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.watchlistnews.com/helen-m-thackray-sells-2000-shares-of-glycomimetics-inc-glyc-stock/1764172.html.

About GlycoMimetics

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.